A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States – EClinicalMedicine
— Read on www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00182-6/fulltext
Observational data from a national clinical laboratory, though limited by an epidemiological view of the U.S. population, offer an encouraging timeline for the development and sustainability of antibodies up to ten months from natural infection and could inform post-pandemic planning.